RxDoctor Payments Data

Kris Miguel Cajipe, MD

Urology · Scottsdale, AZNPI 1912327198

Payments from drug & device makers

$4,503in general payments, 2019–2025

Across 94 payments — averaging $47.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$852
  • Caldera Medical, Inc$812
  • Coloplast$781
  • Procept Biorobotics Corporation$238
  • Intuitive Surgical$237
  • AbbVie$211
  • plus $1K from 24 others

What the payments were for

  • Consulting fees$80018%
  • Travel & lodging$1,10024%
  • Food & beverage$2,58057%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,503 in reported general payments places this provider in the 50th percentile of 269 urology providers in Arizona.

See all urology providers in Arizona

Medicare billing

Part B allowed, 2024
$293,260
Medicare patients
778
Services billed
3,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron176$151,227
MyrbetriqMirabegron88$86,605
Tamsulosin Hcl378$6,050
Alfuzosin Hcl ErAlfuzosin Hcl90$2,041
Testosterone Cypionate16$1,419
Methenamine Hippurate34$1,309
Solifenacin Succinate35$1,082
Finasteride67$1,031
Trospium Chloride12$749
Estradiol12$617
Oxybutynin Chloride ErOxybutynin Chloride65$491
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst24$356
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav35$264
Ciprofloxacin Hcl46$247
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim57$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$22$151,227176 claims
Astellas Pharma US IncMyrbetriq$199$86,60588 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 269 urology providers in Arizona.

Other urology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →